F. Marincola

F. Marincola, D. Venzon, D. White, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA‐Cw*0702‐associated epitope MAGE‐A12:170–178

F. Marincola, S. Mocellin, D. White, 2003, International journal of cancer.

Status of Immune Oncology: Challenges and Opportunities.

F. Marincola, A. Cesano, M. Thurin, 2020, Methods in molecular biology.

Cancer Immunotherapy Principles and Practice

Ke Liu, Pedro Romero, Patricia A. Young, 2018 .

Letter to the editor: Checking the pulse of adoptive cell therapy for solid tumors. Thoughts from the abstracts submitted to the 35th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2020)

F. Marincola, Martina Markovska, 2021, Journal for ImmunoTherapy of Cancer.

Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy

F. Marincola, L. Butterfield, E. Wang, 2020, Journal for ImmunoTherapy of Cancer.

Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading

F. Marincola, S. Mocellin, M. Panelli, 2001, International journal of cancer.

Cancer immunotherapy trials: leading a paradigm shift in drug development

F. Marincola, F. Hodi, L. Butterfield, 2016, Journal of Immunotherapy for Cancer.

Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.

F. Marincola, S. Rosenberg, P. Muranski, 2015, The Journal of clinical investigation.

Timing and intensity of exposure to interferon‐γ critically determines the function of monocyte‐derived dendritic cells

F. Marincola, P. Muranski, J. Melenhorst, 2014, Immunology.

Leukemia cells induce changes in human bone marrow stromal cells

F. Marincola, M. Sabatino, D. Stroncek, 2013, Journal of Translational Medicine.

Immunodominance Across HLA Polymorphism: Implications for Cancer Immunotherapy

F. Marincola, D. Parkinson, Christina J. Kim, 1998, Journal of immunotherapy.

Altered structural brain changes and neurocognitive performance in pediatric HIV

F. Marincola, Rakesh K. Gupta, M. Haris, 2017, NeuroImage: Clinical.

Diagnosis implications of the whole genome sequencing in a large Lebanese family with hyaline fibromatosis syndrome

F. Marincola, E. Chouery, A. Mégarbané, 2017, BMC Genetics.

T cells and IFN-γ. These findings demonstrate that BACH2 is a key component of the molecular program of tumor immunosuppression and identify therapeutic targets for the reversal of immunosuppression in cancer. The transcription factor BACH2 promotes tumor immunosuppression

F. Marincola, K. Okkenhaug, Jenny H. Pan, 2016 .

The transcription factor BACH2 promotes tumor immunosuppression.

F. Marincola, K. Okkenhaug, Jenny H. Pan, 2016, The Journal of clinical investigation.

F. Marincola, P. Ascierto, D. Bedognetti, 2014, Molecular oncology.

F. Marincola, P. Ascierto, D. Bedognetti, 2014, Journal of Translational Medicine.

Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2.

F. Marincola, P. Hwu, E. Wang, 2002, Human gene therapy.

Targeting vaccinia to solid tumors with local hyperthermia.

F. Marincola, S. Chalikonda, D. Bartlett, 2005, Human gene therapy.

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment

F. Marincola, G. Botti, P. Ascierto, 2013, Journal of Translational Medicine.

A balanced review of the status T cell-based therapy against cancer

F. Marincola, 2005, Journal of Translational Medicine.

Correspondence 1: Cancer vaccines: pessimism in check

F. Marincola, S. Mocellin, V. Bronte, 2004, Nature Network Boston.

Melanoma NOS1 expression promotes dysfunctional IFN signaling.

F. Marincola, G. Weiss, S. Rosenberg, 2014, The Journal of clinical investigation.

Tumor‐induced CD11b+ Gr‐1+ myeloid‐derived suppressor cells exacerbate immune‐mediated hepatitis in mice in a CD40‐dependent manner

M. Manns, F. Marincola, J. Berzofsky, 2015, European journal of immunology.

Tailoring cells for clinical needs: Meeting report from the Advanced Therapy in Healthcare symposium (October 28–29 2017, Doha, Qatar)

Peter R Parham, F. Marincola, R. Fuleihan, 2018, Journal of Translational Medicine.

Turning laboratory findings into therapy: a marathon goal that has to be reached.

F. Marincola, D. Stroncek, B. Kotlán, 2009, Polskie Archiwum Medycyny Wewnetrznej.

The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program

F. Marincola, P. Hwu, W. Urba, 2011, Journal of Translational Medicine.

Phase I Trial of Intratumoral Injection of CCL21 Gene–Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration

F. Marincola, F. Abtin, R. Suh, 2017, Clinical Cancer Research.

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients

F. Marincola, D. Bedognetti, M. Maio, 2017, Oncoimmunology.

Melanoma Bridge 2013: Poster and Oral

F. Marincola, A. Ribas, Y. Shoenfeld, 2014 .

Revealing cancer initiating cells in metastatic melanomas by harnessing the host′s anti tumor humoral immune mechanisms

F. Marincola, Y. Shoenfeld, O. Csuka, 2014, Journal of Translational Medicine.

Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin’s Lymphoma Patients Treated with Rituximab-Containing Regimens

F. Marincola, D. Bedognetti, M. Ferrarini, 2011, The Journal of Immunology.

Influence of Quercetin-Rich Food Intake on microRNA Expression in Lung Cancer Tissues

F. Marincola, T. Lam, A. Pesatori, 2012, Cancer Epidemiology, Biomarkers & Prevention.

T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance

F. Marincola, E. Wang, G. Phan, 2001, Expert opinion on biological therapy.

Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population

F. Marincola, D. Bedognetti, S. Adams, 2012, Medical Oncology.

Common pathways to tumor rejection

F. Marincola, D. Bedognetti, E. Wang, 2013, Annals of the New York Academy of Sciences.

Characterization of human melanoma cell lines and melanocytes by proteome analysis

F. Marincola, J. McCubrey, M. Libra, 2011, Cell cycle.

Helper B Cells Promote Cytotoxic T Cell Survival and Proliferation Independently of Antigen Presentation through CD27/CD70 Interactions1

F. Marincola, E. Wang, D. Stroncek, 2008, The Journal of Immunology.

Investigation of residual hepatitis C virus in presumed recovered subjects

F. Marincola, K. Matsuura, H. Alter, 2013, Hepatology.

Cancer Immunotherapy

F. Marincola, U. Kammula, 1999, BioDrugs.

The Development of Cancer Vaccines for the Treatment of Metastatic Melanoma

F. Marincola, S. A. Ronseberg, 1999 .

Cytotoxic T‐cell clone against rectal carcinoma induced by stimulation of a patient's peripheral blood mononuclear cells with autologous cultured tumor cells

F. Marincola, D. Monos, R. Somasundaram, 1997 .

Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.

F. Marincola, S. Rosenberg, N. Restifo, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Kinetics of TCR Use in Response to Repeated Epitope-Specific Immunization

F. Marincola, S. Rosenberg, E. Wang, 2001, The Journal of Immunology.

Genomic scale analysis of racial impact on response to IFN-α

F. Marincola, M. Sabatino, A. Falus, 2009, Proceedings of the National Academy of Sciences.

Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force

F. Marincola, L. Butterfield, M. Disis, 2010, Journal of Translational Medicine.

Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness

F. Marincola, S. Mocellin, E. Wang, 2001, International journal of cancer.

Clonal persistence and evolution during a decade of recurrent melanoma.

F. Marincola, M. Sabatino, E. Wang, 2006, The Journal of investigative dermatology.

The dual role of IL-10.

F. Marincola, S. Mocellin, E. Wang, 2003, Trends in immunology.

Cytokines and Immune Response in the Tumor Microenvironment

F. Marincola, S. Mocellin, E. Wang, 2001, Journal of immunotherapy.

Gene expression profiling of anticancer immune responses.

F. Marincola, E. Wang, M. Panelli, 2004, Current opinion in molecular therapeutics.

GM-CSF/IL-3/IL-5 receptor common β chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells

F. Marincola, E. Wang, D. Stroncek, 2008, Journal of Translational Medicine.

Functional Heterogeneity of Vaccine-Induced CD8+ T Cells1

F. Marincola, S. Rosenberg, E. Wang, 2002, The Journal of Immunology.

Antitumor vaccines, immunotherapy and the immunological constant of rejection.

F. Marincola, M. Sabatino, E. Wang, 2009, IDrugs : the investigational drugs journal.

The Pathway to Biomarker Discovery: Carbonic Anhydrase IX and the Prediction of Immune Responsiveness

F. Marincola, E. Wang, M. Panelli, 2005, Clinical Cancer Research.

Intensity of the Vaccine-Elicited Immune Response Determines Tumor Clearance

F. Marincola, P. Matzinger, N. Restifo, 2002, The Journal of Immunology.

"...we happily celebrate the birth of a new 'Immunotherapy' journal devoted to the identification and publication of salient basic and clinical immunology studies with an open-minded vision, looking for breakthroughs that could explain immunologic phenomena in a comprehensive fashion."

F. Marincola, 2009 .

Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy

F. Marincola, J. Koropatnick, N. Riordan, 2014, Journal of Translational Medicine.

Peptide/MHC Tetramer Analysis

F. Marincola, Peter P. Lee, 2005 .

Development and promotion in translational medicine: perspectives from 2012 sino-american symposium on clinical and translational medicine

F. Marincola, C. Bai, E. Wang, 2012, Clinical and Translational Medicine.

Accommodation to a reduced islet cell mass in dogs.

F. Marincola, R. Merrell, L. Cobb, 1984, The American journal of physiology.

Thrombopoietin and Chemokine mRNA Expression in Patient Post‐Chemotherapy and In Vitro Cytokine‐Treated Marrow Stromal Cell Layers

F. Marincola, U. Kammula, R. Gress, 2000, Stem cells.

Global Analyses of Human Immune Variation Reveal Baseline Predictors of Postvaccination Responses

J. P. McCoy, F. Marincola, Manikandan Narayanan, 2014, Cell.

The Requirements for CTL-Mediated Rejection of Cancer in Humans: NKG2D and Its Role in the Immune Responsiveness of Melanoma

F. Marincola, E. Wang, S. Selleri, 2007, Clinical Cancer Research.

Sequential 5-Aza-2′-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1

F. Marincola, S. Rosenberg, Julie A Hong, 2001, Journal of immunotherapy.

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

F. Marincola, P. Choyke, M. Merino, 2011, The New England journal of medicine.

Islet recovery in chronic pancreatitis.

F. Marincola, R. Merrell, N. Azumi, 1983, The Journal of surgical research.

Natural T cell immunity against cancer.

F. Marincola, C. Scheibenbogen, U. Keilholz, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Frequency of Human Leukocyte Antigen-A 24 Alleles in Patients With Melanoma Determined by Human Leukocyte Antigen-A Sequence-Based Typing

F. Marincola, D. Stroncek, M. Bettinotti, 2000, Journal of immunotherapy.

Distinct signatures of the immune responses in low risk versus high risk neuroblastoma

F. Marincola, E. Wang, M. Manjili, 2011, Journal of Translational Medicine.

Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.

Thomas E. Hughes, F. Marincola, Y. Kotliarov, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.

F. Marincola, J. Mulé, P. Fetsch, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

New HLA-A, -B, and -C locus-specific primers for PCR amplification from cDNA: application in clinical immunology.

F. Marincola, M. Bettinotti, Erin Ruppe, 2003, Journal of immunological methods.

HCV RNA levels in a multiethnic cohort of injection drug users: Human genetic, viral and demographic associations

F. Marincola, T. O'Brien, F. Shebl, 2012, Hepatology.

Quiescent phenotype of tumor-speciﬁc CD8 (cid:1) T cells following immunization

F. Marincola, S. Migueles, M. Connors, 2004 .

Use of laser scanning cytometry to study tumor microenvironment.

F. Marincola, S. Mocellin, E. Wang, 2003, Histology and histopathology.

Characterization of CD8− HLA Class I/Epitope Tetrameric Complexes Binding T Cells

F. Marincola, E. Wang, V. Monsurrò, 2002, Journal of immunotherapy.

The role of quantitative PCR for the immune monitoring of cancer patients

F. Marincola, E. Wang, M. Panelli, 2002, Expert opinion on biological therapy.

Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications

F. Marincola, M. Maio, M. Guidoboni, 2007, Clinical Cancer Research.

Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance

F. Marincola, C. Klebanoff, E. Wang, 2015, Journal for ImmunoTherapy of Cancer.

Immune selection after antigen-specific immunotherapy of melanoma.

S. Steinberg, F. Marincola, S. Rosenberg, 1999, Surgery.

Heterogeneous expression of melanoma‐associated antigens and HLA‐A2 in metastatic melanoma in vivo

S. Steinberg, F. Marincola, S. Rosenberg, 1998, International journal of cancer.

Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.

F. Marincola, J. Gnarra, J. Taubenberger, 1994, Journal of immunology.

Tyrosinase immunoreactivity in fine‐needle aspiration samples of metastatic malignant melanoma

F. Marincola, P. Fetsch, A. Abati, 2000, Cancer.

CD4+, HLA class I‐restricted, cytolytic T‐lymphocyte clone against primary malignant melanoma cells

F. Marincola, D. Guerry, R. Somasundaram, 2000, International journal of cancer.

The use of polyethylene glycol‐modified interleukin‐2 (PEG‐IL‐2) in the treatment of patients with metastatic renal cell carcinoma and melanoma

F. Marincola, S. Rosenberg, J. Yang, 1995, Cancer.

Identification of a Mutated Fibronectin As a Tumor Antigen Recognized by CD4+T Cells

F. Marincola, Helen Y Wang, Rong-Fu Wang, 2002, The Journal of experimental medicine.

Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display.

F. Marincola, D. Elder, P. Gimotty, 2007, Cancer research.

Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases

F. Marincola, R. Clark, N. Wages, 2016, Cancer Immunology, Immunotherapy.

Melanoma vaccines: the paradox of T cell activation without clinical response

F. Marincola, M. Nielsen, 2000, Cancer Chemotherapy and Pharmacology.

Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells.

F. Marincola, M. Murakami, J. Ackland, 1999, Cancer research.

Advances in Brief Induction of Specific CD 8 1 T-Lymphocyte Responses Using a Human Papillomavirus-16 E 6 / E 7 Fusion Protein and Autologous Dendritic Cells

F. Marincola, M. Murakami, J. Ackland, 1999 .

A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies

F. Marincola, L. Butterfield, P. Srivastava, 2012, Journal of Translational Medicine.

Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols.

F. Marincola, G. Parmiani, C. Castelli, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes

David Heckerman, Sharon Adams, Christian Brander, 2006, Nature Immunology.

Extensive HLA class I allele promiscuity among viral CTL epitopes

Nebojsa Jojic, John Sidney, Alessandro Sette, 2007, European journal of immunology.

Increased effector–target cell conjugate formation due to HLA restricted specific antigen recognition

F. Marincola, T. Fleisher, S. Deola, 2009, Immunologic research.

MHC-peptide specificity and T-cell epitope mapping: where immunotherapy starts.

F. Marincola, S. Mocellin, D. Stroncek, 2006, Trends in molecular medicine.

Laser Scanning Cytometry Evaluation of MART-1, gp100, and HLA-A2 Expression in Melanoma Metastases

F. Marincola, S. Rosenberg, S. Mocellin, 2001, Journal of immunotherapy.

a Peptide Vaccine Patients with Metastatic Melanoma Receiving Generation of Antitumor Reactivity in Impact of Cytokine Administration on the

F. Marincola, S. Rosenberg, P. Hwu, 1999 .

A genetic inference on cancer immune responsiveness

F. Marincola, E. Wang, L. Uccellini, 2012, Oncoimmunology.

Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma

F. Marincola, G. Weiss, C. Slingluff, 2011, Clinical Cancer Research.

‘Emergency exit' of bone-marrow-resident CD34+DNAM-1brightCXCR4+-committed lymphoid precursors during chronic infection and inflammation

F. Marincola, E. Wang, S. Boni, 2015, Nature Communications.

Host Response to Cytomegalovirus Infection as a Determinant of Susceptibility to Coronary Artery Disease: Sex-Based Differences in Inflammation and Type of Immune Response

F. Marincola, A. Quyyumi, S. Epstein, 2000, Circulation.

Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes

S. Steinberg, F. Marincola, S. Rosenberg, 2000, International journal of cancer.

Transfusion-transmitted infections

F. Marincola, C. Brander, F. Bihl, 1991, Journal of Translational Medicine.

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

F. Marincola, P. Ascierto, A. Ribas, 2011, Journal of Translational Medicine.

A novel method for efficient generation of antigen-specific effector T-cells using dendritic cells transduced with recombinant adeno-associated virus and p38 kinase blockade

F. Marincola, R. Bresalier, F. Grizzi, 2019, Journal of Translational Medicine.

Direct T cell–tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme

F. Marincola, D. Bedognetti, M. Sabatino, 2014, British Journal of Cancer.

Cancer Therapy : Clinical Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 ( Aldesleukin ) Administration for the Treatment of Metastatic Melanoma

F. Marincola, G. Weiss, C. Slingluff, 2011 .

Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.

S. Steinberg, F. Marincola, S. Rosenberg, 1996, The cancer journal from Scientific American.

Migration deficit in monocyte-macrophages in human ovarian cancer

F. Marincola, E. Wang, D. Stroncek, 2008, Cancer Immunology, Immunotherapy.

The complex role of B7 molecules in tumor immunology.

F. Marincola, B. Seliger, S. Ferrone, 2008, Trends in molecular medicine.

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

F. Marincola, P. Ascierto, M. Atkins, 2020, Journal for ImmunoTherapy of Cancer.

Cancer vaccines at an inflexion point: what next?

F. Marincola, A. Bot, M. Obrocea, 2011, Journal of Translational Medicine.

Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses

F. Marincola, S. Kim-Schulze, H. Kaufman, 2014, Journal of Immunotherapy for Cancer.

What's next in translational medicine?

Mario Plebani, Francesco M Marincola, F. Marincola, 2007, Clinical science.

AAAS joins the Translational Medicine family

F. Marincola, C. Brander, 2009, Journal of Translational Medicine.

Degree of CD14 expression in melanoma infiltrating mononuclear phagocytes.

F. Marincola, P. Fetsch, A. Abati, 2005, Journal of dermatological science.

Different maturation cocktails provide dendritic cells with different chemoattractive properties

F. Marincola, B. Seliger, E. Wang, 2015, Journal of Translational Medicine.

No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study

F. Marincola, P. Ascierto, B. Fox, 2020, Oncoimmunology.

Cytokeratin positivity in fine‐needle aspirates of metastatic malignant melanoma: Fact or fiction?

F. Marincola, P. Fetsch, A. Abati, 1999, Diagnostic cytopathology.

Melan-A/MART-1 antigen expression in cutaneous and ocular melanomas.

F. Marincola, A. Mangoni, P. Natali, 1997, Journal of immunotherapy.

High Throughput Hla Sequence-Based Typing (Sbt) Utilizing the Abi Prism® 3700 Dna Analyzer

F. Marincola, S. Adams, D. Stroncek, 2001, Tumori.

Gene expression profiling of cutaneous wound healing

F. Marincola, E. Wang, D. Stroncek, 2007 .

The modulation of hepatitis C virus 1a replication by PKR is dependent on NF-kB mediated interferon beta response in Huh7.5.1 cells.

S. Jia, F. Marincola, E. Wang, 2013, Virology.

Combination therapy with interferon-γ and interleukin-2 for the treatment of metastatic melanoma

F. Marincola, J. Taubenberger, S. Rosenberg, 1996 .

Intratumoral Gene Signatures and Host Genetic Variations Associated With Immune Responsiveness

F. Marincola, D. Bedognetti, E. Wang, 2021, Cancer Immunotherapy Principles and Practice.

Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study

F. Marincola, P. Delrio, J. Lee, 2022, Cancers.

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond

F. Marincola, P. Ascierto, 2015, EBioMedicine.

NOS1 S-nitrosylates PTEN and inhibits autophagy in nasopharyngeal carcinoma cells

F. Marincola, M. Wang, Lingqun Zhu, 2017, Cell Death Discovery.

Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity.

F. Marincola, E. Appella, C. Geisler, 1998, Critical reviews in immunology.

The multiple ways to tumor tolerance.

F. Marincola, 1997, Journal of immunotherapy.

Melanoma antigen expression in serial fine‐needle aspiration samples in patients with metastatic malignant melanoma participating in immunotherapy clinical trials

S. Steinberg, F. Marincola, P. Fetsch, 2001, Cancer.

Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.

F. Marincola, L. D. Da Pozzo, W. Holder, 1990, Surgery.

Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade

F. Marincola, M. Gilbert, W. Ho, 2018, Nature Communications.

Suppression, Stress, and Accommodation of Transplanted Islets of Langerhans

F. Marincola, R. Merrell, G. Basadonna, 1985, Diabetes.

Melanoma‐associated antigen recognized by T cells (MART‐1)

F. Marincola, D. Kleiner, P. Fetsch, 1999, Cancer.

International Meeting “Immunotherapy of Cancer: Challenges and Needs”

F. Marincola, F. Belardelli, M. Ferrantini, 2007, Cancer Immunology, Immunotherapy.

Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases

F. Marincola, N. Wages, C. Slingluff, 2016, Cancer Immunology, Immunotherapy.

Characterization of viscosupplementation formulations using chemical exchange saturation transfer (ViscoCEST)

J. B. Kneeland, F. Marincola, R. Reddy, 2016, Journal of Translational Medicine.

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

F. Marincola, P. Hwu, E. Wang, 2015, Oncoimmunology.

Inaugural Charles River World Congress on Animal Models in Drug Discovery and Development

F. Marincola, D. L. Taylor, J. Berzofsky, 2017, Journal of Translational Medicine.

RH genotyping in a sickle cell disease patient contributing to hematopoietic stem cell transplantation donor selection and management.

F. Marincola, A. Monaco, D. Stroncek, 2010, Blood.

This information is current as Activation Differences in Immune Signaling Pathway Donors Reveals Age-and Race-Associated Blood Mononuclear Cells from Healthy Single-Cell Network Profiling of Peripheral Cesano

F. Marincola, Diane M. Longo, E. Wang, 2012 .

Peripheral Circulating CD45RA-FOXP3hi T Regulatory (TReg) II Cells Provide a Window into the Activity of Intratumoral TReg Cells.

F. Marincola, S. Pai, 2020, Trends in cancer.

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule

F. Marincola, J. Galon, S. Demaria, 2016, Journal of Immunotherapy for Cancer.

Clinical Applications of Activated Immune Cells

F. Marincola, M. Sabatino, D. Stroncek, 2011 .

Applying the uncertainty principle to immunology.

F. Marincola, E. Wang, 2011, Immunotherapy.

Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

F. Marincola, P. Choyke, M. Merino, 2011 .

Emerging Therapeutics for Melanoma

F. Marincola, P. Ascierto, J. Kirkwood, 2012 .

Islet cell isolation in experimental d,l-ethionine pancreatitis in dogs.

F. Marincola, R. Merrell, N. Azumi, 1985, The Journal of surgical research.

Cancer therapy using a self-replicating RNA vaccine

F. Marincola, K. Irvine, T. Zaks, 1999, Nature Medicine.

Clinical and translational medicine: Integrative and practical science.

F. Marincola, E. Abraham, Zhi-nan Chen, 2012, Clinical and Translational Medicine.

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

F. Marincola, P. Ascierto, D. Bedognetti, 2011, BMC Cancer.

142 Contextual reprogramming of CAR T cells for the treatment of HER2-expressing cancers

F. Marincola, Hana Choi, Zhifen Yang, 2020, Journal for ImmunoTherapy of Cancer.

RegimensPatients Treated with Rituximab-Containing Depletion in Non-Hodgkin's Lymphoma Associated with Persistent Memory B Cell Impaired Response to Influenza Vaccine

Paolo, F. Marincola, M. Ferrarini, 2011 .

Effusion cytology of malignant melanoma

F. Marincola, P. Fetsch, A. Abati, 1997, Cancer.

Current strategies employed in the manipulation of gene expression for clinical purposes

F. Marincola, Violena Pietrobon, Hsing-Chuan Tsai, 2022, Journal of Translational Medicine.

Standardized in-vitro evaluation of CAR-T cells using acellular artificial target particles

F. Marincola, Kyung-Ho Roh, Rona Harari-Steinfeld, 2022, Frontiers in Immunology.

154 Context-dependent reversible modulation of cJUN expression by CAR T cells for cancer treatment

F. Marincola, Zhifen Yang, 2021, Journal for ImmunoTherapy of Cancer.

INHIBITION OF ACTIVATION OF LYMPHOKINE-ACTIVATED KILLER CELLS IN VITRO BY THE HEPARIN PRESERVATIVE BENZYL ALCOHOL

F. Marincola, W. Holder, B. Drucker, 1987, The Lancet.

Cytotoxic T-cell clone against rectal carcinoma induced by stimulation of a patient's peripheral blood mononuclear cells with autologous cultured tumor cells.

F. Marincola, D. Monos, R. Somasundaram, 1997, International journal of cancer.

Pyrosequencing™ : A one-step method for high resolution HLA typing

F. Marincola, S. Adams, Lu Wang, 2003, Journal of Translational Medicine.

HLA associations with nasopharyngeal carcinoma.

F. Marincola, E. Wang, Xin Li, 2009, Current molecular medicine.

Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function

F. Marincola, H. Bear, M. Manjili, 2009, Journal of Translational Medicine.

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients

F. Marincola, P. Ascierto, H. Khalak, 2013, Journal of Translational Medicine.

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

F. Marincola, B. Seliger, D. Bedognetti, 2016, Journal of Translational Medicine.

Meta-analysis and metagenes

F. Marincola, D. Bedognetti, E. Wang, 2014, Oncoimmunology.

Molecular immune signatures of HIV‐1 vaccines in human PBMCs

F. Marincola, M. Sabatino, F. Buonaguro, 2009, FEBS letters.

Doppler examination in varicocele. A standard method of evaluation.

F. Marincola, F. Annoni, L. Negri, 1988, Journal of andrology.

HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients.

F. Marincola, S. Adams, D. Stroncek, 2006, Blood.

Metastatic melanoma: Correlation of MRI characteristics and histopathology

F. Marincola, J. Taubenberger, D. Venzon, 1996, Journal of magnetic resonance imaging : JMRI.

Erratum to: Diagnosis implications of the whole genome sequencing in a large Lebanese family with hyaline fibromatosis syndrome

W. Liu, F. Marincola, E. Chouery, 2017, BMC Genetics.

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2

R. Simon, F. Marincola, S. Rosenberg, 2013, British Journal of Cancer.

Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science.

F. Marincola, D. Stroncek, B. Kotlán, 2009, Immunotherapy.

Sequence uniqueness and sequence variability as modulating factors of human anti-HCV humoral immune response

F. Marincola, L. Tessitore, A. Kusalik, 2008, Cancer Immunology, Immunotherapy.

Widespread and ample peptide overlapping between HCV and Homo sapiens proteomes

F. Marincola, Y. Li, A. Kusalik, 2007, Peptides.

Cytokine and chemokine expression profiles of maturing dendritic cells using multiprotein platform arrays.

Francesco M Marincola, Dirk Nagorsen, F. Marincola, 2004, Cytokine.

The influence of diet on anti-cancer immune responsiveness

F. Marincola, P. Ascierto, L. Soldati, 2018, Journal of Translational Medicine.

Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells

Gianni Cesareni, Marco Orecchioni, Kostas Kostarelos, 2017, Nature Communications.

Bacterial Growth in Venous Ulcers of the Lower Extremity and Its Sensitivity to Antibiotics

F. Marincola, M. Rosina, F. Annoni, 1989 .

A HCMV pp65 polypeptide promotes the expansion of CD4+ and CD8+ T cells across a wide range of HLA specificities

F. Marincola, D. Stroncek, L. Bracci, 2009, Journal of cellular and molecular medicine.

Identification of Immune Dominant Cytomegalovirus Epitopes Using Quantitative Real-Time Polymerase Chain Reactions to Measure Interferon-&ggr; Production by Peptide-Stimulated Peripheral Blood Mononuclear Cells

F. Marincola, S. Mocellin, D. Stroncek, 2002, Journal of immunotherapy.

Comparison of proteomic profiles of serum, plasma, and modified media supplements used for cell culture and expansion

F. Marincola, D. Stroncek, M. Panelli, 2006, Journal of Translational Medicine.

Defining the critical hurdles in cancer immunotherapy

Zhigang Tian, Sylvia Janetzki, Cedrik M Britten, 2011, Journal of Translational Medicine.

Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.

F. Marincola, E. Trimble, A. Sette, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.

John Mao, Francesco M Marincola, F. Marincola, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value

F. Marincola, Y. Shoenfeld, O. Csuka, 2015, Immunologic research.

The novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value

F. Marincola, Y. Shoenfeld, O. Csuka, 2014, Immunologic Research.

Interferon-γ Reduces Melanosomal Antigen Expression and Recognition of Melanoma Cells by Cytotoxic T Cells

Adam I. Riker, Francesco M. Marincola, Ena Wang, 2002 .

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

F. Marincola, P. Vandenabeele, S. Loi, 2020, Journal for ImmunoTherapy of Cancer.

Human mesenchymal stromal cell-secreted lactate induces M2-macrophage differentiation by metabolic reprogramming

Ping Jin, Florina Moldovan, Francesco M. Marincola, 2016, Oncotarget.

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.

S. Steinberg, F. Marincola, S. Rosenberg, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Diagnostics for Melanoma

F. Marincola, M. Thurin, 2014, Methods in Molecular Biology.

What have we learned from cancer immunotherapy in the last 3 years?

F. Marincola, P. Ascierto, 2014, Journal of Translational Medicine.

Global Analyses of Human Immune Variation Reveal Baseline Predictors of Postvaccination Responses

Yuri Kotliarov, Wei Wang, Manikandan Narayanan, 2014, Cell.

Stem cells in melanoma development.

F. Marincola, M. Sabatino, E. Wang, 2009, Cancer letters.

Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor.

F. Marincola, K. Batts, P. Fetsch, 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

BACH2 represses effector programmes to stabilize Treg-mediated immune homeostasis - a new target in tumor immunotherapy?

F. Marincola, D. Bedognetti, B. Dema, 2013, Journal of Immunotherapy for Cancer.

Expansion of Tumor-T Cell Pairs from Fine Needle Aspirates of Melanoma Metastases

F. Marincola, S. Rosenberg, E. Wang, 2000, The Journal of Immunology.

Needle Aspirates of Melanoma Metastases Expansion of Tumor-T Cell Pairs from Fine Marincola

F. Marincola, S. Rosenberg, E. Wang, 1999 .

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

F. Marincola, C. Maccalli, V. Inchakalody, 2023, Molecular Cancer.

130 Immunogenic potential of chimeric antigen receptor (CAR)-engineered T cells expressing inducible nuclease-deactivated SpCas9 (dCas9)

F. Marincola, Maggie L. Bobbin, A. Cesano, 2020, Journal for ImmunoTherapy of Cancer.

Improving CAR T-Cell Persistence

F. Marincola, Zhifen Yang, Violena Pietrobon, 2021, International journal of molecular sciences.

Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014

Martin F. Mihm, B. Schilling, F. Marincola, 2013, Journal of Translational Medicine.

Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”

F. Marincola, J. Taube, G. Botti, 2013, Journal of Translational Medicine.

Tumour immunity: effector response to tumour and role of the microenvironment

F. Marincola, A. Palucka, A. Mantovani, 2008, The Lancet.

Phase 1 Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From the Melanoma-Associated Antigens MART-1 and gp100

F. Marincola, S. Rosenberg, E. Wang, 2000, Journal of immunotherapy.

Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients

F. Marincola, R. Galli, E. Wang, 2010, Clinical Cancer Research.

Germline genetic contribution to the immune landscape of cancer

Rosalyn W. Sayaman, V. Thorsson, F. Marincola, 2020, bioRxiv.

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story.

S Ferrone, F. Marincola, D. Hicklin, 1999, Molecular medicine today.

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.

F. Marincola, G. Trinchieri, R. Goldszmid, 2011, The Journal of clinical investigation.

Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line.

F. Marincola, W. Linehan, S. Rosenberg, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

The new melanoma markers: MART-1 and Melan-A (the NIH experience)

F. Marincola, P. Fetsch, A. Abati, 1999, The American journal of surgical pathology.

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

Mark S. Sundrud, F. Marincola, S. Rosenberg, 2015, Cancer research.

A Tumor-Infiltrating Lymphocyte from a Melanoma Metastasis with Decreased Expression of Melanoma Differentiation Antigens Recognizes MAGE-12

F. Marincola, S. Rosenberg, M. Panelli, 2000, The Journal of Immunology.

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

F. Marincola, S. Rosenberg, P. Hwu, 1998, Journal of the National Cancer Institute.

Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma

F. Marincola, G. V. Vande Woude, M. Berens, 2015, Journal of Translational Medicine.

Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma

F. Marincola, G. V. Vande Woude, E. Wang, 2011, Proceedings of the National Academy of Sciences.

Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy

Karl J. Dykema, F. Marincola, R. Schlegel, 2013, Genes & cancer.

A signature of immune function genes associated with recurrence-free survival in breast cancer patients

F. Marincola, H. Bear, E. Wang, 2012, Breast Cancer Research and Treatment.

Potency analysis of cellular therapies: the role of molecular assays

F. Marincola, M. Sabatino, E. Wang, 2021, Principles of Translational Science in Medicine.

Potency Analysis of Cellular Therapies

F. Marincola, M. Sabatino, E. Wang, 2015 .

Global Transcriptional Analysis for Biomarker Discovery and Validation in Cellular Therapies

F. Marincola, M. Sabatino, E. Wang, 2012, Molecular Diagnosis & Therapy.

Quality assessment of cellular therapies: the emerging role of molecular assays

F. Marincola, M. Sabatino, E. Wang, 2010, The Korean journal of hematology.

Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies

Ping Jin, Francesco M Marincola, Ena Wang, 2010, Journal of Translational Medicine.

Global transcriptional analysis for biomarker discovery and validation in cellular therapies.

Ping Jin, Francesco M Marincola, Marianna Sabatino, 2009, Molecular diagnosis & therapy.

Effects of Systemically Administered Hydrocortisone on the Human Immunome

J. P. McCoy, F. Marincola, G. Trinchieri, 2016, Scientific Reports.

Monoallelic expression in melanoma

Hakeem G. Almabrazi, F. Marincola, B. Seliger, 2019, Journal of Translational Medicine.

Correction: A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival

T. Hudson, F. Marincola, M. Ceccarelli, 2020, British Journal of Cancer.

A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival

T. Hudson, F. Marincola, M. Ceccarelli, 2020, British Journal of Cancer.

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis

F. Marincola, F. Bertucci, M. Ceccarelli, 2017, Oncoimmunology.

Analyzing T Cell Responses

F. Marincola, D. Nagorsen, 2005 .

Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)

F. Marincola, E. Appella, M. Nishimura, 1996, The Journal of experimental medicine.

Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness

F. Marincola, C. Print, L. Miller, 2016, Cancer immunology research.

Biomarkers for Immunotherapy of Cancer: Methods and Protocols

F. Marincola, A. Cesano, M. Thurin, 2020 .

The Biology of Immune-Active Cancers and Their Regulatory Mechanisms.

F. Marincola, D. Bedognetti, E. Wang, 2020, Cancer treatment and research.

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)

F. Marincola, G. Botti, P. Ascierto, 2018, Journal of Translational Medicine.

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)

F. Marincola, B. Wallden, P. Danaher, 2018, Journal of Immunotherapy for Cancer.

Harnessing the immune system for the treatment of melanoma: current status and future prospects

F. Marincola, B. Seliger, D. Bedognetti, 2016, Expert review of clinical immunology.

Checkpoint Inhibitors and Their Application in Breast Cancer

F. Marincola, B. Seliger, D. Bedognetti, 2016, Breast Care.

Prognostic and predictive immune gene signatures in breast cancer

Davide Bedognetti, Francesco M Marincola, F. Marincola, 2015, Current opinion in oncology.

Quantitative real-time PCR in cancer research.

F. Marincola, S. Mocellin, C. Rossi, 2003, Archivum immunologiae et therapiae experimentalis.

Evolution of Metastases in Space and Time under Immune Selection

F. Marincola, M. Ceccarelli, J. Galon, 2018, Cell.

IL-10 stimulatory effects on human NK cells explored by gene profile analysis

F. Marincola, S. Mocellin, E. Wang, 2004, Genes and Immunity.

MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells

Ping Jin, Francesco M Marincola, Ena Wang, 2009, Journal of Translational Medicine.

Inherited polymorphisms in the RNA-mediated interference machinery affect microRNA expression and lung cancer survival

F. Marincola, L. Burdette, A. Bergen, 2010, British Journal of Cancer.

Temple-Baraitser Syndrome and Zimmermann-Laband Syndrome: one clinical entity?

D. MacArthur, F. Marincola, M. Lek, 2016, BMC Medical Genetics.

Gene profiling of immune responses against tumors.

Francesco M Marincola, Ena Wang, F. Marincola, 2005, Current opinion in immunology.

Melanoma-restricted genes

F. Marincola, N. Hu, Phil R. Taylor, 2004, Journal of Translational Medicine.

Different maturation cocktails provide dendritic cells with different chemoattractive properties

F. Marincola, B. Seliger, E. Wang, 2015, Journal of Translational Medicine.

Cytokine polymorphism and its possible impact on cancer

F. Marincola, E. Wang, M. Panelli, 2004, Immunologic research.

A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings

F. Marincola, R. Simon, S. Adams, 2003, Journal of Translational Medicine.

Two hits in one: whole genome sequencing unveils LIG4 syndrome and urofacial syndrome in a case report of a child with complex phenotype

F. Marincola, R. Crystal, E. Wang, 2016, BMC Medical Genetics.

Melanoma Cell Propagation: Cancer Stem Cell, Clonal Evolution and Interconversion Models of Tumorigenicity

F. Marincola, M. Sabatino, E. Wang, 2012 .

Cancer Stem Cells in Melanoma

F. Marincola, M. Sabatino, E. Wang, 2011 .

TGFβR2 is a major target of miR-93 in nasopharyngeal carcinoma aggressiveness

F. Marincola, E. Wang, W. Cho, 2014, Molecular Cancer.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Joseph F. Murphy, V. Thorsson, F. Marincola, 2019, Journal of Immunotherapy for Cancer.

Metastatic lesions with and without interleukin-18-dependent genes in advanced-stage melanoma patients.

F. Marincola, M. Sabatino, E. Wang, 2013, The American journal of pathology.

Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation

Francesco M. Marincola, Luigi Buonaguro, Ena Wang, 2008, BMC Bioinformatics.

The Tumor Microenvironment as a Model for Tissue-Specific Rejection

F. Marincola, C. Rumio, S. Selleri, 2008 .

Tumor microenvironment and the immune response.

F. Marincola, M. Sabatino, E. Wang, 2007, Surgical oncology clinics of North America.

Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation

F. Marincola, F. Buonaguro, L. Buonaguro, 2005, Journal of Translational Medicine.

The role of BRAF V600 mutation in melanoma

F. Marincola, P. Ascierto, J. Kirkwood, 2012, Journal of Translational Medicine.

Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma

F. Marincola, D. Bedognetti, E. Wang, 2014, Expert opinion on biological therapy.

TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness.

F. Marincola, J. Malek, S. Bedri, 2013, Cancer research.

Molecular and Cellular Pathobiology TNRC 9 Downregulates BRCA 1 Expression and Promotes Breast Cancer Aggressiveness

F. Marincola, J. Malek, S. Bedri, 2013 .

MicroRNA Expression Differentiates Histology and Predicts Survival of Lung Cancer

Yingdong Zhao, Neil E. Caporaso, Maria Teresa Landi, 2010, Clinical Cancer Research.

MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18

F. Marincola, G. Trinchieri, E. Wang, 2010, The Journal of experimental medicine.

miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy

F. Marincola, M. Lotze, E. Wang, 2010, Journal of Translational Medicine.

The stable traits of melanoma genetics: an alternate approach to target discovery

F. Marincola, D. Bedognetti, E. Wang, 2012, BMC Genomics.

Chapter 59 – Cancer Biometrics

F. Marincola, M. Panelli, 2005 .

Immunotherapy against antigenic tumors: a game with a lot of players

F. Marincola, A. Perez-Diez, 2002, Cellular and Molecular Life Sciences CMLS.

An immunologic portrait of cancer

F. Marincola, D. Bedognetti, E. Wang, 2011, Journal of Translational Medicine.

The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer

F. Marincola, F. Bertucci, D. Birnbaum, 2018, British Journal of Cancer.

Immune oncology, immune responsiveness and the theory of everything

T. Hudson, F. Marincola, L. Butterfield, 2018, Journal of Immunotherapy for Cancer.

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk

F. Marincola, G. Coukos, D. Bedognetti, 2016, Oncoimmunology.

F. Marincola, P. Ascierto, D. Bedognetti, 2014, Journal of Translational Medicine.

Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy

F. Marincola, D. Bedognetti, E. Wang, 2015 .

Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology

F. Marincola, J. Malek, E. Wang, 2013, The Journal of investigative dermatology.

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes

F. Marincola, D. Bedognetti, E. Wang, 2013, British Journal of Cancer.

Molecular Profiling of Immunotherapeutic Resistance

F. Marincola, D. Bedognetti, E. Wang, 2013 .

IRF5 gene polymorphisms in melanoma

F. Marincola, R. Simon, S. Rosenberg, 2012, Journal of Translational Medicine.

The stable traits of melanoma genetics: an alternate approach to target discovery

F. Marincola, D. Bedognetti, E. Wang, 2012, BMC Genomics.

Immunologic signatures of rejection

F. Marincola, E. Wang, 2011 .

The immunologic constant of rejection.

F. Marincola, E. Wang, A. Worschech, 2008, Trends in immunology.

Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis.

F. Marincola, M. Sabatino, E. Wang, 2008, Cancer research.

Common cancer biomarkers.

Yingdong Zhao, Nan Hu, Katia Zavaglia, 2006, Cancer research.

Ontogeny and Oncogenesis Balance the Transcriptional Profile of Renal Cell Cancer

F. Marincola, B. Seliger, E. Wang, 2004, Cancer Research.

Selection and validation of endogenous reference genes using a high throughput approach

F. Marincola, N. Hu, Phil R. Taylor, 2004, BMC Genomics.

Tumors as elusive targets of T-cell-based active immunotherapy.

Soldano Ferrone, Francesco M Marincola, Meenhard Herlyn, 2003, Trends in immunology.

Functional Genome Profiling to Understand Cancer Immune Responsiveness.

F. Marincola, D. Bedognetti, E. Wang, 2020, Methods in molecular biology.

Chemotherapy enhances vaccine‐induced antitumor immunity in melanoma patients

F. Marincola, E. Wang, F. Cognetti, 2009, International journal of cancer.

HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.

F. Marincola, D. Venzon, S. Rosenberg, 1992, Cancer research.

Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer

F. Marincola, P. Delrio, J. Lee, 2023, Cancers.

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.

F. Marincola, P. Delrio, G. Botti, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications

F. Marincola, P. Kuppen, D. Bedognetti, 2017, International journal of molecular sciences.

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients

F. Marincola, P. Ascierto, H. Khalak, 2013, Journal of Translational Medicine.

Loss of connective tissue growth factor as an unfavorable prognosis factor activates miR-18b by PI3K/AKT/C-Jun and C-Myc and promotes cell growth in nasopharyngeal carcinoma

F. Marincola, E. Wang, Q. Fu, 2013, Cell Death and Disease.

Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta.

F. Marincola, D. Monos, R. Swoboda, 2002, Cancer research.

Ran signaling in melanoma: implications for the development of alternative therapeutic strategies.

F. Marincola, G. Botti, P. Ascierto, 2015, Cancer letters.

Inflammatory protein profile during systemic high dose interleukin‐2 administration

F. Marincola, G. Hortin, E. Wang, 2006, Proteomics.

Consensus nomenclature for CD 8 T cell phenotypes in cancer

S. H. van der Burg, J. Blay, F. Marincola, 2015 .

Interleukin‐10 and the immune response against cancer: a counterpoint

F. Marincola, S. Mocellin, H. Young, 2005, Journal of leukocyte biology.

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015

F. M. Marincola, F. Marincola, G. Botti, 2016, Journal of Translational Medicine.

Single versus combination immunotherapy drug treatment in melanoma

F. Marincola, P. Ascierto, A. Grimaldi, 2016, Expert opinion on biological therapy.

Venotonic activity of escin on the human saphenous vein.

F. Marincola, L. Resele, F. Annoni, 1979, Arzneimittel-Forschung.

Analysis of a high‐throughput HLA antibody screening assay for use with platelet donors

F. Marincola, S. Adams, D. Stroncek, 2008, Transfusion.

Genomic landscape of tumor-host interactions with differential prognostic and predictive connotations

F. Marincola, F. Bertucci, M. Ceccarelli, 2019, bioRxiv.

Conditional activation of immune-related signatures and prognostic significance: a pan-cancer analysis

F. Marincola, F. Bertucci, M. Ceccarelli, 2019 .

Tumor-Associated Inflammation and Impact on Dendritic Cell Function

F. Marincola, M. Sabatino, A. Falus, 2009 .

Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection

F. Marincola, E. Wang, Yong A. Yu, 2011, BMC Cancer.

EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN

F. Marincola, E. Wang, K. Yao, 2014, Oncogene.

Induction of pro-inflammatory programs in enteroendocrine cells by the Toll-like receptor agonists flagellin and bacterial LPS.

F. Marincola, E. Wang, C. Rumio, 2008, International immunology.

Lentiviral delivery of combinatorial CAR/CRISPRi circuit into human primary T cells is enhanced by TBK1/IKKɛ complex inhibitor BX795

Lei S. Qi, F. Marincola, Zhifen Yang, 2020, Journal of translational medicine.

Targeted Therapy Database (TTD): A Model to Match Patient's Molecular Profile with Current Knowledge on Cancer Biology

Jeff Shrager, Randy Gobbel, Simone Mocellin, 2010, PloS one.

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

F. Marincola, P. Ascierto, B. Seliger, 2017, European journal of cancer.

Revealing cancer initiating cells in metastatic melanomas by harnessing the host′s anti tumor humoral immune mechanisms

F. Marincola, Y. Shoenfeld, O. Csuka, 2014, Journal of Translational Medicine.

Melanoma Bridge 2013: Poster and Oral Presentations

F. Marincola, R. Mancini, M. Pisanu, 2014 .

A novel method for efficient generation of antigen-specific effector T-cells using dendritic cells transduced with recombinant adeno-associated virus and p38 kinase blockade

F. Marincola, R. Bresalier, F. Grizzi, 2019, Journal of Translational Medicine.

Preliminary report of a novel formulation of clinical-grade, fully matured, tumor-associated peptide-loaded dendritic cells for cancer immunotherapy

F. Marincola, R. Bresalier, M. Chiriva-Internati, 2019, Translational Medicine Communications.

Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis

F. Marincola, E. Wang, D. Stroncek, 2008, Journal of Translational Medicine.

Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments

F. Marincola, E. Wang, F. Belardelli, 2011, Journal of Translational Medicine.

Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”

F. Marincola, P. Ascierto, G. Ciliberto, 2013, Journal of translational medicine.

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer

F. Marincola, J. Heath, S. Rosenberg, 2012, Journal of Translational Medicine.

Translational Medicine - doing it backwards

A. Schechter, F. Marincola, R. Nussenblatt, 2010, Journal of Translational Medicine.

Linkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma?

Francesco M Marincola, Ena Wang, F. Marincola, 2011, Journal of proteome research.

Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma

Friedrich Lottspeich, Roland Kellner, Francesco M Marincola, 2009, Proteomics.

Fast-Lane Evolution in the Tumor Microenvironment

F. Marincola, G. Marincola, 2006 .

Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape

F. Marincola, Manikandan Narayanan, Suresh Cuddapah, 2015, Cellular and Molecular Immunology.

Obesity susceptibility loci in Qataris, a highly consanguineous Arabian population

F. Marincola, E. Wang, L. Chouchane, 2015, Journal of Translational Medicine.

Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer.

F. Marincola, E. Wang, M. Deavers, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

CRISPR technology for immuno-oncology applications.

F. Marincola, Jianbin Wang, V. Balan, 2019, Methods in enzymology.

Association of IFN-γ Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines

F. Marincola, B. Seliger, G. Pawelec, 2011, Clinical Cancer Research.

Association of IFN-g Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines

F. Marincola, B. Seliger, G. Pawelec, 2011 .

A CD4+, HLA‐DR7‐restricted T‐helper lymphocyte clone recognizes an antigen shared by human malignant melanoma and glioma

F. Marincola, R. Swoboda, D. Guerry, 2003, International journal of cancer.

Forecasting the cytokine storm following systemic interleukin (IL)-2 administration

F. Marincola, E. Wang, M. Panelli, 2004, Journal of Translational Medicine.

HLA-A2-Restricted HIV-1 Gag p24 Repertoire Specific for the Subdominant T Cell + Availability of a Diversely Avid CD8

F. Marincola, C. Brander, N. Frahm, 2017 .

Availability of a Diversely Avid CD8+ T Cell Repertoire Specific for the Subdominant HLA-A2-Restricted HIV-1 Gag p2419–27 Epitope1

M. Altfeld, F. Marincola, O. Yang, 2007, The Journal of Immunology.

Chapter 10 – Human Leukocyte and Granulocyte Antigens and Antibodies: The HLA and HNA Systems

F. Marincola, S. Adams, E. Wang, 2007 .

Evaluation of gene expression profiles of immature dendritic cells prepared from peripheral blood mononuclear cells

F. Marincola, E. Wang, D. Stroncek, 2008, Transfusion.

Different Requirements for Signal Transducer and Activator of Transcription 1α and Interferon Regulatory Factor 1 in the Regulation of Low Molecular Mass Polypeptide 2 and Transporter Associated with Antigen Processing 1 Gene Expression*

Soldano Ferrone, Francesco M. Marincola, F. Marincola, 1998, The Journal of Biological Chemistry.

Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells

F. Marincola, E. Wang, M. Magnani, 2017, Journal of Virology.

Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities

F. M. Marincola, Nicole Frahm, B. Walker, 2004, Journal of Virology.

Differences in the expressed HLA class I alleles effect the differential clustering of HIV type 1-specific T cell responses in infected Chinese and caucasians.

Todd M. Allen, M. Altfeld, B. Walker, 2004, AIDS research and human retroviruses.

Chapter 113 – Human Leukocyte Antigen and Human Neutrophil Antigen Systems

F. Marincola, S. Adams, E. Wang, 2018 .

Let-7 microRNAs are developmentally regulated in circulating human erythroid cells

F. Marincola, S. Goh, Y. T. Lee, 2009, Journal of Translational Medicine.

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

S. H. van der Burg, F. Marincola, A. Palucka, 2011, Clinical Cancer Research.

Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.

A Sette, F. Marincola, A. Sette, 1995, Journal of immunology.

Molecular Signatures Associated with HCV-Induced Hepatocellular Carcinoma and Liver Metastasis

F. Marincola, F. Izzo, F. Buonaguro, 2013, PloS one.

Epitope-Specific Immunization Kinetics of TCR Use in Response to Repeated

Steven A. Rosenberg, Francesco M. Marincola, Mark E. Dudley, 2013 .

Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates.

F. Marincola, E. Wang, Yingdong Zhao, 2012, Human gene therapy methods.

Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon‐mediated rejection genes

Federico Garrido, Francesco M Marincola, Ena Wang, 2012, International journal of cancer.

Immune-Mediated Tumor Rejection

F. Marincola, E. Wang, 2011 .

Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment

Yingdong Zhao, Davide Bedognetti, Francesco M Marincola, 2011, BMC Medical Genomics.

CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer

F. Marincola, E. Wang, S. Holt, 2011, Breast Cancer Research and Treatment.

Gene-expression profiling in vaccine therapy and immunotherapy for cancer

F. Marincola, D. Bedognetti, E. Wang, 2010, Expert review of vaccines.

Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.

F. Marincola, A. Ribas, E. Wang, 2009, Cancer research.

Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma

F. Marincola, F. Izzo, F. Buonaguro, 2009, Journal of Translational Medicine.

Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

F. Marincola, B. Comin-Anduix, A. Ribas, 2009, Clinical Cancer Research.

Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy

Qian Zhang, Francesco M Marincola, Marianna Sabatino, 2009, BMC Genomics.

Evaluation of 3 Clinical Dendritic Cell Maturation Protocols Containing Lipopolysaccharide and Interferon-γ

F. Marincola, D. Stroncek, Jiaqiang Ren, 2009, Journal of immunotherapy.

Cancer Therapy: Clinical Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

F. Marincola, B. Comin-Anduix, A. Ribas, 2009 .

Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.

F. Marincola, H. Bear, E. Wang, 2008, Cancer research.

Characterization of tumor-directed cellular immune responses in humans

F. Marincola, V. Monsurrò, D. Nagorsen, 2008 .

Comparative Analysis of Peritoneum and Tumor Eicosanoids and Pathways in Advanced Ovarian Cancer

F. Marincola, E. Wang, M. Deavers, 2007, Clinical Cancer Research.

Deciphering the molecular machinery of stem cells: a look at the neoblast gene expression profile

F. Marincola, E. Wang, A. Lena, 2007, Genome Biology.

Gene profiling for the prediction of tumor response to treatment: the case of immunotherapy.

F. Marincola, V. Monsurrò, 2007, Advances in experimental medicine and biology.

Complementary techniques: RNA amplification for gene profiling analysis.

F. Marincola, E. Wang, M. Panelli, 2007, Advances in experimental medicine and biology.

ComparativeAnalysis of Peritoneum andTumor Eicosanoids and Pathways in Advanced Ovarian Cancer

F. Marincola, M. Deavers, R. Newman, 2007 .

Gene expression profiling of cutaneous wound healing

F. Marincola, E. Wang, D. Stroncek, 2007, Journal of Translational Medicine.

Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection

F. Marincola, E. Wang, Yingdong Zhao, 2007, Genome Biology.

Journal of Translational Medicine Molecular Signatures Induced by Interleukin-2 on Peripheral Blood Mononuclear Cells and T Cell Subsets

F. Marincola, E. Wang, D. Stroncek, 2022 .

RNA Amplification for Gene Profiling Analysis

F. Marincola, E. Wang, M. Panelli, 2006 .

Infectious pathogen detection arrays: viral detection in cell lines and postmortem brain tissue.

Francesco M Marincola, Ena Wang, F. Marincola, 2005, BioTechniques.

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.

F. Marincola, E. Wang, H. Kaufman, 2005, The Journal of clinical investigation.

Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms

F. Marincola, E. Wang, D. Stroncek, 2005, Journal of Translational Medicine.

Polarized monocyte response to cytokine stimulation

F. Marincola, E. Wang, M. Panelli, 2005, Genome Biology.

Quiescent phenotype of tumor-specific CD8+ T cells following immunization.

Mark Connors, Steven Jacobson, Francesco M Marincola, 2004, Blood.

A Genomic- and Proteomic-Based Hypothesis on the Eclectic Effects of Systemic Interleukin-2 Administration in the Context of Melanoma-Specific Immunization

F. Marincola, E. Wang, M. Panelli, 2004, Cells Tissues Organs.

A global approach to tumor immunology.

F. Marincola, E. Wang, M. Panelli, 2004, Cellular & molecular immunology.

DNA Array-Based Gene Profiling in Tumor Immunology

F. Marincola, S. Mocellin, E. Wang, 2004, Clinical Cancer Research.

The Development and Reversal of T-Cell Tolerance in Cancer Patients Receiving Peptide-Based Vaccines

F. Marincola, E. Wang, 2004 .

Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines.

F. Marincola, S. Mocellin, D. Nitti, 2003, Biochimica et biophysica acta.

Tumor Microenvironment: What have we Learned Studying the Immune Response in this Puzzling Battlefield?

F. Marincola, S. Mocellin, E. Wang, 2002, Tumori.

Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness.

Yingdong Zhao, Richard Simon, Paul H Duray, 2002, Cancer research.

Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration

F. Marincola, L. Miller, E. Wang, 2002, Genome Biology.

The impact of genomics on the biotechnology industry

F. Marincola, E. Wang, M. Panelli, 2001, Expert opinion on biological therapy.

Short-Term Kinetics of Tumor Antigen Expression in Response to Vaccination

F. Marincola, S. Rosenberg, S. Mocellin, 2001, The Journal of Immunology.

T-cell-directed cancer vaccines: the melanoma model

Francesco M Marincola, Ena Wang, F. Marincola, 2001, Expert opinion on biological therapy.

Journal of Translational Medicine Forecasting the Cytokine Storm following Systemic Interleukin (il)-2 Administration Background

F. Marincola, E. Wang, M. Panelli, 2022 .

The immunologic aspects of poxvirus oncolytic therapy

F. Marincola, E. Wang, D. Stroncek, 2009, Cancer Immunology, Immunotherapy.

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers

F. Marincola, D. Venzon, S. Khleif, 2008, Cancer Immunology, Immunotherapy.

Immunogenic cell death in cancer: concept and therapeutic implications

F. Marincola, L. Galluzzi, O. Kepp, 2023, Journal of Translational Medicine.

Heterogeneity in expression of human leukocyte antigens and melanoma‐associated antigens in advanced melanoma

F. Marincola, G. A. Ohnmacht, Galen A. Ohnmacht, 2000, Journal of cellular physiology.

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

Francesco M Marincola, Licia Rivoltini, Piero Dalerba, 2002, Journal of the National Cancer Institute.

Cooperativity of adaptive and innate immunity: implications for cancer therapy

F. Marincola, A. Shanker, 2011, Cancer Immunology, Immunotherapy.

Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity

F. Marincola, S. Rosenberg, L. Gritz, 2006, Annals of Surgical Oncology.

Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.

F. Marincola, J. Cormier, M. Panelli, 1998, Journal of immunology.

Implications for Peptide-Based Immunotherapy MART-1 / Melan A Immunodominance : Stringent Allele / Epitope Requirements for

F. Marincola, J. Cormier, M. Panelli, 1998 .

Antigens Recognizes MAGE-12 Expression of Melanoma Differentiation Melanoma Metastasis with Decreased A Tumor-Infiltrating Lymphocyte from a Rosenberg and

F. Marincola, S. Rosenberg, M. Panelli, 2000 .

Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod

F. Marincola, A. Heguy, S. Demaria, 2019, Scientific Reports.

Systems biology applied to vaccine and immunotherapy development

Francesco M. Marincola, Luigi Buonaguro, Ena Wang, 2011, BMC Systems Biology.

Generation of robust CD8+ T‐cell responses against subdominant epitopes in conserved regions of HIV‐1 by repertoire mining with mimotopes

F. Marincola, J. Sidney, A. Sette, 2010, European journal of immunology.

Dynamic Nature of Tumour-Host Interactions Within the Tumor Microenvironment

F. Marincola, D. Nagorsen, 2005 .

Gene alterations as predictors of radiation-induced toxicity in head and neck squamous cell carcinoma

F. Marincola, V. Moiseenko, P. Sanghvi, 2021, Journal of translational medicine.

Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment

F. Marincola, M. Maggiolini, R. Lappano, 2022, Cancers.

A Multi-Factorial Genetic Model for Prognostic Assessment of High Risk Melanoma Patients Receiving Adjuvant Interferon

F. Marincola, J. Kirkwood, H. Gogas, 2012, PloS one.

A road map to Translational Medicine in Qatar and a model for the world

F. Marincola, J. Sheikh, 2012, Journal of Translational Medicine.

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment

F. Marincola, P. Ascierto, J. Kirkwood, 2010, Journal of Translational Medicine.

Immunologic Interpretation of Cancer Biology: Impact on Clinical Outcome

F. Marincola, E. Wang, M. Ascierto, 2013 .

Lost in Translation: Obstacles to Translational Medicine

Soldano Ferrone, Christian Brander, Francesco M Marincola, 2004, Journal of Translational Medicine.

Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy

F. Marincola, P. Queirolo, F. Spagnolo, 2014, Archives of Dermatological Research.

Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest

James J. Morrow, F. Marincola, M. Raffeld, 2014, Cancer Immunology Research.

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)

F. Marincola, G. Botti, P. Ascierto, 2019, Journal of Translational Medicine.

Melanoma: prognostic factors and factors predictive of response to therapy.

F. Marincola, P. Ascierto, M. Strudel, 2019, Current medicinal chemistry.

The nude mouse as a model for the study of human pancreatic cancer.

W D Holder, F. Marincola, F M Marincola, 1989, The Journal of surgical research.

Orthotopic and heterotopic xenotransplantation of human pancreatic cancer in nude mice.

F. Marincola, W. Holder, C. Taylor-Edwards, 1987, Current surgery.

Cancer immune resistance: can theories converge?

F. Marincola, J. Samayoa, Tolga Turan, 2017, Emerging topics in life sciences.

Epstein–Barr virus microRNAs and lung cancer

F. Marincola, M. Gulley, A. Goldstein, 2011, British Journal of Cancer.

Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy.

F. Marincola, W. Leonard, P. Muranski, 2016, Cell metabolism.

Advantages of mRNA amplification for microarray analysis.

S K Libutti, F. Marincola, A. Feldman, 2002, BioTechniques.

The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle.

F. Marincola, S. Mocellin, D. Nitti, 2004, Cytokine & growth factor reviews.

Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells

F. Marincola, M. Panelli, S. Finkelstein, 2003, Gene Therapy.

Activation and Propagation of Tumor-infiltrating Lymphocytes on Clinical-grade Designer Artificial Antigen-presenting Cells for Adoptive Immunotherapy of Melanoma

Christopher Toth, Francesco M Marincola, Ena Wang, 2014, Journal of immunotherapy.

Differential Responses of Plasmacytoid Dendritic Cells to Influenza Virus and Distinct Viral Pathogens

Gregory M. Frank, F. Marincola, G. Trinchieri, 2014, Journal of Virology.

Understanding the response to immunotherapy in humans

F. Marincola, E. Wang, M. Panelli, 2005, Springer Seminars in Immunopathology.

Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy

F. Marincola, H. Levitsky, W. Kast, 2004, Journal of Translational Medicine.

Combination therapy: the next opportunity and challenge of medicine

Paolo A Ascierto, Francesco M Marincola, F. Marincola, 2011, Journal of Translational Medicine.

Monocyte-derived DC maturation strategies and related pathways: a transcriptional view

F. Marincola, M. Sabatino, A. Krensky, 2011, Cancer Immunology, Immunotherapy.

Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination.

F. Marincola, P. Fetsch, A. Abati, 1998, Journal of immunology.

A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"

Yingdong Zhao, Holden Maecker, Sylvia Janetzki, 2008, Journal of Translational Medicine.

Reflections upon human cancer immune responsiveness to T cell-based therapy

F. Marincola, E. Wang, S. Tomei, 2012, Cancer Immunology, Immunotherapy.

Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”, Napoli, December 5th-8th 2013

B. Schilling, F. Marincola, R. Sullivan, 2014, Journal of Translational Medicine.

Selection factors resulting in improved survival after surgical resection of tumors metastatic to the lungs.

F. Marincola, J. B. Mark, 1990, Archives of surgery.

A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice

F. Marincola, T. Donlon, W. Holder, 1988, In Vitro Cellular & Developmental Biology.

Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration

S. Steinberg, F. Marincola, S. Rosenberg, 2014, Clinical Cancer Research.

Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells.

F. Marincola, E. Wang, June K. Robinson, 2002, The American journal of pathology.

Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.

F. Marincola, E. Appella, M. Salgaller, 1996, Journal of immunology.

Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient

F. Marincola, E. Sigurdson, R. Swoboda, 2009, International journal of cancer.

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015

F. Marincola, P. Ascierto, B. Fox, 2016, Journal of Immunotherapy for Cancer.

“Immune B Cells know it better”: tumorimmunological panel assay to define tumor-associated antigen binding antibodies in patients with metastatic melanomas

F. Marincola, O. Csuka, G. Liszkay, 2015, Journal of Translational Medicine.

Minor tumor infiltrating B cells opened a door to reveal and eliminate cancer initiating cells in metastatic melanomas

F. Marincola, O. Csuka, G. Liszkay, 2014, Journal of Immunotherapy for Cancer.

Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions

F. Marincola, A. Bot, K. Smith, 2013, Expert review of vaccines.

Overview of melanoma vaccines and promising approaches

F. Marincola, E. Wang, M. Panelli, 2004, Current oncology reports.

Vaccination with T cell-defined antigens

F. Marincola, E. Wang, M. Panelli, 2004, Expert opinion on biological therapy.

Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis

F. Marincola, D. Bedognetti, E. Wang, 2011, Journal of Translational Medicine.

Prediction of response to anticancer immunotherapy using gene signatures.

F. Marincola, D. Bedognetti, E. Wang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In support of descriptive studies; relevance to translational research

F. Marincola, 2007, Journal of Translational Medicine.

Rewarding patient-directed research: Excellence in Translational Medicine Award

Soldano Ferrone, Christian Brander, Francesco M Marincola, 2006, Journal of Translational Medicine.

Obstacles and opportunities in translational research

F. Marincola, Heidi Hörig, Elizabeth Marincola, 2005, Nature Medicine.

Frequency of MART-1/MelanA and gp100/PMel17-Specific T Cells in Tumor Metastases and Cultured Tumor-Infiltrating Lymphocytes

F. Marincola, S. Rosenberg, E. Wang, 2002, Journal of immunotherapy.

Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.

F. Marincola, S. Rosenberg, P. Hwu, 1999, Journal of immunology.

Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an In vitro melanoma model

F. Marincola, S. Ferrone, A. Mixon, 1999, International journal of cancer.

Racial differences in B cell receptor signaling pathway activation

F. Marincola, Diane M. Longo, E. Wang, 2012, Journal of Translational Medicine.

The immune score as a new possible approach for the classification of cancer

F. Marincola, P. Ascierto, G. Trinchieri, 2012, Journal of Translational Medicine.

Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha.

F. Marincola, S. Rosenberg, J. Mulé, 1994, Journal of immunology.

Antimelanoma CTL recognizes peptides derived from an ORF transcribed from the antisense strand of the 3′ untranslated region of TRIT1

F. Marincola, M. Herlyn, R. Swoboda, 2015, Molecular therapy oncolytics.

Functional characterization of CTL against gp100 altered peptide ligands

F. Marincola, D. Lake, S. O. Dionne, 2003, Cancer Immunology, Immunotherapy.

A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology.

F. Marincola, M. Panelli, K. H. Lee, 1999, Journal of immunological methods.

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.

F. Marincola, M. Sabatino, E. Wang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

What’s new in melanoma? Combination!

F. Marincola, P. Ascierto, M. Atkins, 2015, Journal of Translational Medicine.

Evaluation of cognitivity, proinflammatory cytokines, and brain magnetic resonance imaging in minimal hepatic encephalopathy induced by cirrhosis and extrahepatic portal vein obstruction

F. Marincola, Rakesh K. Gupta, M. Haris, 2016, Journal of gastroenterology and hepatology.

Title Evaluation of cognitivity , proinflammatory cytokines , and brain magnetic resonance imaging in minimal hepatic encephalopathy induced by cirrhosis and extrahepatic portal vein obstruction Permalink

F. Marincola, Rakesh K. Gupta, M. Haris, 2016 .

Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors

F. Marincola, H. Rammensee, E. Wang, 2013, Journal of Immunotherapy for Cancer.

Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination.

F. Marincola, S. Rosenberg, U. Kammula, 2000, Journal of the National Cancer Institute.

Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells

F. Marincola, S. Stevanović, B. Seliger, 2011, Proteomics.

Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting

F. Marincola, R. Puri, L. Zitvogel, 2013, Journal of Immunotherapy for Cancer.

Functional Heterogeneity of Vaccine-Induced

Steven A. Rosenberg, Francesco M. Marincola, Mark E. Dudley, 2013 .

Spontaneous and treatment-induced cancer rejection in humans

F. Marincola, M. Sabatino, E. Wang, 2008 .

Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100209-217 and gp100209-217T210M

F. Marincola, C. Servis, M. Dudley, 2004, Cancer Immunology, Immunotherapy.

F. Marincola, H. Kaiser, D. Nagorsen, 2002, In Vivo.

The matrix protein pp65341‐350: a peptide that induces ex vivo stimulation and in vitro expansion of CMV‐specific CD8+ T cells in subjects bearing either HLA‐A*2402 or A*0101 allele

F. Marincola, S. Mocellin, D. Stroncek, 2003, Transfusion.

Advancing Cancer Biotherapy with Proteomics

F. Marincola, B. Martin, D. Stroncek, 2005, Journal of immunotherapy.

A natural history of melanoma: serial gene expression analysis.

F. Marincola, E. Wang, 2000, Immunology today.

A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Nystatin on the Development of Oral Irritation in Patients Receiving High-Dose Intravenous Interleukin-2

S. Steinberg, F. Marincola, S. Rosenberg, 2001, Journal of immunotherapy.

Selective Histocompatibility Leukocyte Antigen (Hla)-A2 Loss Caused by Aberrant Pre-mRNA Splicing in 624mel28 Melanoma Cells

F. Marincola, S. Ferrone, G. Parmiani, 1999, The Journal of experimental medicine.

Immunomics of Immune Rejection

F. Marincola, M. Sabatino, E. Wang, 2009 .

The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2

F. Marincola, A. Sewell, Darcy B. Wilson, 2006, Cancer Immunology, Immunotherapy.

Autologous Tumor Rejection in Humans: Trimming the Myths

F. Marincola, E. Wang, M. Panelli, 2006, Immunological investigations.

Analysis of vaccine-induced T cells in humans with cancer.

F. Marincola, E. Wang, D. Stroncek, 2010, Advances in experimental medicine and biology.

Inter-donor variation in cell subset specific immune signaling responses in healthy individuals.

F. Marincola, Diane M. Longo, E. Wang, 2012, American journal of clinical and experimental immunology.

Monitoring Antigen-specific T Cell Responses

F. Marincola, D. Nagorsen, 2005 .

Revisiting the paradigm on the putative need for antigen-specific responses in cancer

F. Marincola, A. Bot, M. Obrocea, 2015 .

Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients.

DuPont Guerry, Francesco M Marincola, Laszlo Otvos, 2006, Cancer research.

Active-specific immunization against melanoma: is the problem at the receiving end?

F. Marincola, J. Even, E. Wang, 2003, Seminars in cancer biology.

CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects

F. Marincola, S. Adams, D. Stroncek, 2007, Journal of Translational Medicine.

Comprehensive epitope mapping of the Epstein–Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals

F. Marincola, S. Adams, E. Wang, 2007, Cancer Immunology, Immunotherapy.

Immunotherapy of melanoma: the good news, the bad ones and what to do next.

F. Marincola, S. Ferrone, 2003, Seminars in cancer biology.

Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers

Lei S. Qi, F. Marincola, Hana Choi, 2020, Journal of translational medicine.

Discordant cellular and humoral immune responses to cytomegalovirus infection in healthy blood donors: existence of a Th1-type dominant response.

F. Marincola, S. Epstein, G. Shearer, 2001, International immunology.

The role of germline genetics in shaping the tumor immune landscape is largely unknown. Using genotypes from >9,000

Denise, Wolf, Rosalyn W. Sayaman, 2020 .

The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier.

F. Marincola, S. Pai, A. Cesano, 2020, Cancer treatment and research.

Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype

F. Marincola, D. Bedognetti, E. Wang, 2016, Scientific Reports.

Toward the identification of genetic determinants of breast cancer immune responsiveness

F. Marincola, M. Ceccarelli, H. Bensmail, 2015, Journal of Immunotherapy for Cancer.

The sialyl-glycolipid SSEA 4 marks a subpopulation of chemotherapy resistant breast cancer cells with mesenchymal features

F. Marincola, C. Hudis, M. Ceccarelli, 2015 .

Quality controls in cellular immunotherapies: rapid assessment of clinical grade dendritic cells by gene expression profiling.

Yingdong Zhao, Raj K Puri, Francesco M Marincola, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Altered Gray Matter Volume and Structural Connectivity in Pediatric Cirrhotic

F. Marincola, Rakesh K. Gupta, M. Haris, 2016 .

Evaluation of normalization methods for two-channel microRNA microarrays

F. Marincola, L. McShane, E. Wang, 2010, Journal of Translational Medicine.

Immune Responsiveness of Human Tumours

F. Marincola, E. Wang, 2006 .

Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy

F. Marincola, S. Beghelli, A. Scarpa, 2010, Journal of Translational Medicine.

Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma

F. Marincola, B. Seliger, O. Mandelboim, 2016, Oncotarget.

Toward integrative cancer immunotherapy: targeting the tumor microenvironment

F. Marincola, J. Galon, L. Emens, 2012, Journal of Translational Medicine.

Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment

Lei S. Qi, F. Marincola, Hana Choi, 2023, Journal of Translational Medicine.

The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy

F. Marincola, G. Coukos, D. Powell, 2015, Clinical Cancer Research.

Hemodynamic effects of the administration of tumor-infiltrating lymphocytes to cancer patients.

F. Marincola, S. Topalian, D. Parkinson, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

HLA and cancer: 12th International Histocompatibility Workshop study

F. Marincola, W. Bodmer, G. Ferrara, 1997 .

miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis.

F. Marincola, C. Trautwein, S. Bortoluzzi, 2013, Immunity.

Proteomic signature of myeloproliferation and neutrophilia: analysis of serum and plasma from healthy subjects given granulocyte colony-stimulating factor.

F. Marincola, D. Stroncek, J. Tisdale, 2005, Experimental hematology.

Single-Cell Network Profiling of Peripheral Blood Mononuclear Cells from Healthy Donors Reveals Age- and Race-Associated Differences in Immune Signaling Pathway Activation

F. Marincola, J. Ptacek, Diane M. Longo, 2012, The Journal of Immunology.

Research translation: a new frontier for clinical laboratories

F. Marincola, M. Plebani, 2006, Clinical chemistry and laboratory medicine.

Prolonged survival of nude mice bearing human pancreatic cancer and treated with lymphokine-activated killer cells and interleukin-2.

F. Marincola, L. D. Da Pozzo, W. Holder, 1989, Current surgery.

The challenge of implementing high-throughput technologies in clinical trials.

Simone Mocellin, Francesco M Marincola, F. Marincola, 2005, Pharmacogenomics.

Effects of storage time and exogenous protease inhibitors on plasma protein levels.

Francesco M Marincola, F. Marincola, D. Stroncek, 2006, American journal of clinical pathology.

"Sequencing-grade" screening for BRCA1 variants by oligo-arrays

F. Marincola, A. Paradiso, M. Sabatino, 2008, Journal of Translational Medicine.

Associations between HLA Class I alleles and the prevalence of nasopharyngeal carcinoma (NPC) among Tunisians

F. Marincola, S. Adams, E. Wang, 2007, Journal of Translational Medicine.

Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.

F. Marincola, P. Munson, R. Danner, 2007, Cancer research.

Caveolin-1 enhances resveratrol-mediated cytotoxicity and transport in a hepatocellular carcinoma model

F. Marincola, E. Wang, D. Stroncek, 2009, Journal of Translational Medicine.

A decade plus of translation: what do we understand?

Xiangdong Wang, Francesco M Marincola, F. Marincola, 2012, Clinical and Translational Medicine.

The perception of nanotechnology and nanomedicine: a worldwide social media study.

Lucia Gemma Delogu, Alberto Bianco, Davide Bedognetti, 2014, Nanomedicine.

Preamble to the 2015 SITC immunotherapy biomarkers taskforce

F. Marincola, B. Fox, L. Butterfield, 2015, Journal of Immunotherapy for Cancer.

Characterization of viscosupplementation formulations using chemical exchange saturation transfer (ViscoCEST)

J. B. Kneeland, F. Marincola, R. Reddy, 2016, Journal of Translational Medicine.

Lactate Chemical Exchange Saturation Transfer (LATEST) Imaging in vivo A Biomarker for LDH Activity

Ravinder Reddy, Mohammad Haris, Hari Hariharan, 2016, Scientific Reports.

What’s new in melanoma? Combination!

F. Marincola, P. Ascierto, M. Atkins, 2015, Journal of Translational Medicine.

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

F. Marincola, S. Kesari, L. Butterfield, 2019, Journal of Translational Medicine.

Sugar alcohol provides imaging contrast in cancer detection

F. Marincola, M. Schnall, L. Rich, 2019, Scientific Reports.

Non-caloric sweetener provides magnetic resonance imaging contrast for cancer detection

F. Marincola, M. Schnall, R. Reddy, 2017, Journal of Translational Medicine.

An integrated tumor, immune and microbiome atlas of colon cancer

Rosalyn W. Sayaman, Tariq Ahmad Masoodi, F. Marincola, 2023, Nature Medicine.

Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer

F. Marincola, Xiang-dong Wang, William Wang, 2014, Journal of Translational Medicine.

Molecular magnetic resonance imaging in cancer

Ravinder Reddy, Ashutosh Kumar Singh, Mohammad Haris, 2015, Journal of Translational Medicine.

cDNA arrays and the enigma of melanoma immune responsiveness.

F. Marincola, E. Wang, 2001, Cancer journal.

IFN-conditioned dendritic cells for the therapy of melanoma: what is missing?

F. Marincola, T. Ichim, N. Riordan, 2011, Journal of immunotherapy.

Microarray Analysis for a Comprehensive Immunological-Status Evaluation during Cancer Vaccine Immune Monitoring

Francesco M. Marincola, F. Marincola, V. Monsurrò, 2011, Journal of biomedicine & biotechnology.

Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens.

F. Marincola, D. Bedognetti, M. Ferrarini, 2012, Blood.

previously treated with rituximab containing regimens vaccines in complete remission non-Hodgkin lymphoma patients adjuvanted influenza

F. Marincola, M. Ferrarini, F. Ansaldi, 2013 .

Gender-based analysis of cortical thickness and structural connectivity in Parkinson’s disease

Arijitt Borthakur, Elias R. Melhem, Suyash Mohan, 2016, Journal of Neurology.

Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod

F. Marincola, A. Heguy, S. Demaria, 2019, Scientific Reports.

NGS technology applied to melanoma cell lines

F. Marincola, D. Bedognetti, E. Wang, 2013, Journal of Immunotherapy for Cancer.

Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer

F. Marincola, V. Sondak, E. Jaffee, 2011, Journal of Translational Medicine.

Tailoring cells for clinical needs: Meeting report from the Advanced Therapy in Healthcare symposium (October 28–29 2017, Doha, Qatar)

F. Marincola, E. Wang, W. Wels, 2018, Journal of Translational Medicine.

Molecular magnetic resonance imaging in cancer

F. Marincola, R. Reddy, M. Haris, 2015, Journal of Translational Medicine.

Bottom up: a modular view of immunology.

Francesco M Marincola, Ena Wang, F. Marincola, 2008, Immunity.

Reduced cortical thickness in patients with acute-on-chronic liver failure due to non-alcoholic etiology

F. Marincola, Rakesh K. Gupta, S. Rutella, 2015, Journal of Translational Medicine.

15 kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the transcriptome level

F. Marincola, M. Sabatino, E. Wang, 2011, Journal of Translational Medicine.

High-dimensional analysis of the aging immune system: Verification of age-associated differences in immune signaling responses in healthy donors

F. Marincola, J. Ptacek, D. Spellmeyer, 2014, Journal of Translational Medicine.

Translational Medicine is developing in China: A new venue for collaboration

Francesco M Marincola, Ena Wang, F. Marincola, 2011, Journal of Translational Medicine.

Chapter 1A. Structure and Function of IL-10 and the IL-10 Receptor

F. Marincola, 2006 .

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

F. Marincola, S. Kesari, L. Butterfield, 2019, Journal of Translational Medicine.

World-Wide Immunoscore Task Force: meeting report from the “Melanoma Bridge”, Napoli, November 30th–December 3rd, 2016

F. Marincola, P. Ascierto, J. Galon, 2017, Journal of Translational Medicine.

Editorial: Lymphocyte Functional Crosstalk and Regulation

F. Marincola, R. Srivastava, A. Shanker, 2019, Front. Immunol..

Cancer Diagnostic and Predictive Biomarkers

Francesco M Marincola, Maria Lina Tornesello, Franco M Buonaguro, 2014, BioMed research international.

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)

F. Marincola, G. Botti, P. Ascierto, 2019, Journal of Translational Medicine.

Racial differences in B cell receptor signaling pathway activation

F. Marincola, Diane M. Longo, E. Wang, 2012, Journal of Translational Medicine.

Expanding the perspective of translational medicine: the value of observational data

F. Marincola, M. Liebman, 2012, Journal of Translational Medicine.

The challenge of studying complex diseases undergoing complex treatments: the metastatic cancer model

F. Marincola, E. Wang, 2012, Journal of Translational Medicine.

Monoallelic expression in melanoma

Hakeem G. Almabrazi, F. Marincola, B. Seliger, 2016, Journal of translational medicine.

Inherent transcriptional signatures of NK cells are associated with response to IFNα + rivabirin therapy in patients with Hepatitis C Virus

F. Marincola, D. Bedognetti, K. Matsuura, 2015, Journal of Translational Medicine.

Inflammatory Protein Profile During Systemic High Dose Interleukin-2 Administration

F. Marincola, G. Hortin, E. Wang, 2005 .

Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy.

F. Marincola, E. Wang, D. Stroncek, 2007, Critical Reviews in Immunology.

From the “Delayed Allergy Reaction” to the “Immunologic Constant of Rejection”

F. Marincola, E. Wang, 2011 .

Obesity susceptibility loci in Qataris, a highly consanguineous Arabian population

F. Marincola, E. Wang, J. Sheikh, 2015, Journal of Translational Medicine.

Methods to measure vaccine immunity

F. Marincola, V. Apostolopoulos, 2010, Expert Review of Vaccines.

Editorial: Lymphocyte functional crosstalk and regulation, volume II

F. Marincola, R. Srivastava, A. Shanker, 2023, Frontiers in Immunology.

Erratum to: Diagnosis implications of the whole genome sequencing in a large Lebanese family with hyaline fibromatosis syndrome

F. Marincola, E. Chouery, A. Mégarbané, 2017, BMC Genetics.

Bridging the Divide between Science and Journalism

F. Marincola, Laura Van Eperen, Jennifer C. Strohm, 2010, Journal of Translational Medicine.

The "Excellence in Translational Medicine" and "Bedside-to-Bench" Awards 2008-09

F. Marincola, P. Natali, R. Ablin, 2010, Journal of Translational Medicine.

Spontaneous and treatment-induced cancer rejection in humans.

F. Marincola, M. Sabatino, E. Wang, 2008, Expert opinion on biological therapy.

Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells

F. Marincola, G. Cesareni, D. Bedognetti, 2017, Nature Communications.

Phase I S tudy o f t he I ntravenous A dministration o f Attenuated Salmonella t yphimurium to P atients W ith Metastatic M elanoma

F. Marincola, S. Rosenberg, P. Hwu, 2002 .

Interferon- (cid:1) Reduces Melanosomal Antigen Expression and Recognition of Melanoma Cells by Cytotoxic T Cells

F. Marincola, E. Wang, B. Nickoloff, 2022 .

Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.

F. Marincola, P. Ascierto, I. Nagtegaal, 2019, Journal of Clinical Oncology.

Patients Treated with Rituximab-Containing Immunochemotherapy Have a Significant and Prolonged Lack of Humoral Response to Influenza Vaccine Associated with a Persistent Depletion of B Memory Cells.

F. Marincola, D. Bedognetti, M. Sabatino, 2009 .

A global resource to translational medicine: the International Park of Translational Medicine and BioMedicine (IPTBM)

F. Marincola, M. Liebman, Xiangdong Wang, 2013, Journal of Translational Medicine.

Create a translational medicine knowledge repository - Research downsizing, mergers and increased outsourcing have reduced the depth of in-house translational medicine expertise and institutional memory at many pharmaceutical and biotech companies: how will they avoid relearning old lessons?

Francesco M Marincola, F. Marincola, Bruce H Littman, 2011, Journal of Translational Medicine.

Evaluation of normalization methods for two-channel microRNA microarrays

F. Marincola, L. McShane, E. Wang, 2010, Journal of Translational Medicine.

Hepatic myeloid-derived suppressor cells in tumor bearing mice exacerbate hepatitis and transform into pro-inflammatory myeloid cells

M. Manns, F. Marincola, J. Berzofsky, 2013, Journal of Immunotherapy for Cancer.

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

F. Marincola, J. Taubenberger, S. Rosenberg, 1996, Journal of the National Cancer Institute.

Future perspectives in melanoma research

F. Marincola, J. Taube, G. Botti, 2016, Journal of Translational Medicine.

HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.

F. Marincola, C. Hallahan, S. Migueles, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

F. Marincola, S. Rosenberg, J. Cormier, 1997, The cancer journal from Scientific American.

Extensive HLA class I binding promiscuity among EBV- and HIV- derived cytotoxic T lymphocyte epitopes

Karina Yusim, Sharon Adams, F. M. Marincola, 2004 .

Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers

Lei S. Qi, Dharmesh M. Patel, F. Marincola, 2021, Journal of Translational Medicine.

Chromosomal imbalances in nasopharyngeal carcinoma: a meta-analysis of comparative genomic hybridization results

F. Marincola, E. Wang, Yingdong Zhao, 2006, Journal of Translational Medicine.

The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer

F. Marincola, F. Bertucci, D. Birnbaum, 2018, British Journal of Cancer.

Myeloid cells are enriched in tonsillar crypts providing insight into the host tropism of HPV.

F. Marincola, D. Bedognetti, A. Mattox, 2021, The American journal of pathology.

Supporting the advancement of science: Open access publishing and the role of mandates

F. Marincola, Lisa Phelps, B. Fox, 2012, Journal of Translational Medicine.

Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations.

F. Marincola, J. Berzofsky, L. Helman, 2001, Cancer research.

Single‐Voxel 1H MR spectroscopy of cerebral nicotinamide adenine dinucleotide (NAD+) in humans at 7T using a 32‐channel volume coil

Joanne C. Beer, F. Marincola, J. Detre, 2020, Magnetic resonance in medicine.

Significant differences in outcome between Immunoscore categories in stage I colon cancer patients.

F. Marincola, P. Ascierto, I. Nagtegaal, 2019, Annals of Oncology.

Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine.

F. Marincola, B. Moss, S. Rosenberg, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Visceral metastases from melanoma: findings on MR imaging.

F. Marincola, L. Sanders, D. Schwartzentruber, 1992, AJR. American journal of roentgenology.

Metastatic Melanoma: Correlation of

F. Marincola, J. Taubenberger, C. Chow, 1996 .

Comprehensive Epitope Mapping of the Epstein-Barr Virus Latent Membrane Protein-2 in Ethnically Diverse Populations

F. Marincola, S. Adams, E. Wang, 2005 .

A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification.

Sabri Boughorbel, Michele Ceccarelli, Scott R. Presnell, 2017, F1000Research.

Future perspectives in melanoma research

F. Marincola, J. Taube, G. Botti, 2016, Journal of Translational Medicine.

Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014

Martin F. Mihm, B. Schilling, F. Marincola, 2013, Journal of Translational Medicine.

Global Analyses of Human Immune Variation Reveal Baseline Predictors of Postvaccination Responses

F. Marincola, Manikandan Narayanan, D. Chaussabel, 2014, Cell.

Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma

F. Marincola, G. Weiss, C. Slingluff, 2011, Clinical Cancer Research.

Human Cancer Biology Microrna Expression Differentiates Histology and Predicts Survival of Lung Cancer Clinical Cancer Research Authors' Affiliations: Divisions of 1 Cancer Epidemiology and Genetics and 2 Cancer Treatment and Diagnosis

F. Marincola, M. Tucker, A. Goldstein, 2022 .

Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest

James J. Morrow, F. Marincola, M. Raffeld, 2014, Cancer Immunology Research.

Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis.

F. Marincola, M. Sabatino, E. Wang, 2008, Cancer research.

Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”

F. Marincola, J. Taube, G. Botti, 2013, Journal of Translational Medicine.

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

F. Marincola, A. Dzutsev, Y. Belkaid, 2013, Science.

The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.

F. Marincola, J. Galon, D. Bedognetti, 2013, Immunity.

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

F. Marincola, P. Choyke, M. Merino, 2011, The New England journal of medicine.

Association of IFN-γ Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines

F. Marincola, B. Seliger, G. Pawelec, 2011, Clinical Cancer Research.

Tumor‐induced CD11b+ Gr‐1+ myeloid‐derived suppressor cells exacerbate immune‐mediated hepatitis in mice in a CD40‐dependent manner

M. Manns, F. Marincola, J. Berzofsky, 2015, European journal of immunology.

Introducing the society for immunotherapy of cancer’s new journal: journal for immunoTherapy of cancer

F. Marincola, P. Romero, Tara Withington, 2013, Journal of Immunotherapy for Cancer.

Introduction of article-processing charges (APCs) for articles accepted for publication in the Journal of Translational Medicine

F. Marincola, 2003, Journal of Translational Medicine.

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients

F. Marincola, D. Bedognetti, M. Maio, 2017, Oncoimmunology.

The immunologic constant of rejection.

F. Marincola, E. Wang, A. Worschech, 2008, Trends in immunology.

Evaluation of 3 Clinical Dendritic Cell Maturation Protocols Containing Lipopolysaccharide and Interferon-γ

F. Marincola, D. Stroncek, Jiaqiang Ren, 2009, Journal of immunotherapy.

Journal of Translational Medicine Molecular Signatures Induced by Interleukin-2 on Peripheral Blood Mononuclear Cells and T Cell Subsets

F. Marincola, E. Wang, D. Stroncek, 2006 .

Evolution of Metastases in Space and Time under Immune Selection

F. Marincola, M. Ceccarelli, J. Galon, 2018, Cell.

Journal of Translational Medicine Gene Expression Profiling of Cutaneous Wound Healing

F. Marincola, E. Wang, D. Stroncek, 2022 .

MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies

F. Marincola, P. Ascierto, I. Nagtegaal, 2018, Annals of Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Expanding the perspective of translational medicine: the value of observational data

F. Marincola, M. Liebman, 2012, Journal of Translational Medicine.

The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy

F. Marincola, G. Coukos, D. Bedognetti, 2015, Clinical Cancer Research.

HCV RNA levels in a multiethnic cohort of injection drug users: Human genetic, viral and demographic associations

F. Marincola, T. O'Brien, F. Shebl, 2012, Hepatology.

TGFR2 is a major target of miR-93 in nasopharyngeal carcinoma aggressiveness.

F. Marincola, E. Wang, W. Fang, 2022 .

Conference Scene: Immunotherapy reaches new milestones in cancer eradication.

F. Marincola, M. Shurin, V. Umansky, 2011, Immunotherapy.

MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells

F. Marincola, E. Wang, D. Stroncek, 2009, Journal of Translational Medicine.

Journal of Translational Medicine Differentiation of Two Types of Mobilized Peripheral Blood Stem Cells by Microrna and Cdna Expression Analysis

F. Marincola, E. Wang, D. Stroncek, 2022 .

Impact of carbon nanotubes and graphene on immune cells

F. Marincola, D. Bedognetti, A. Bianco, 2014, Journal of Translational Medicine.

TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness.

F. Marincola, J. Malek, S. Bedri, 2013, Cancer Research.

Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy

F. Marincola, M. Sabatino, E. Wang, 2009, BMC Genomics.

Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science.

F. Marincola, D. Stroncek, B. Kotlán, 2009, Immunotherapy.

Evidence for CD19B–CD8T cell interactions in blood and tissues from patients with GvHD

F. Marincola, S. Rutella, E. Wang, 2016, Bone Marrow Transplantation.

Journal of Translational Medicine Gene Expression Profiling of Cutaneous Wound Healing

F. Marincola, E. Wang, D. Stroncek, 2022 .

Editorial: Systems Biology Methods in Computational Immuno-Oncology

F. Marincola, Mohamed Uduman, A. Rodin, 2022, Frontiers in Genetics.

Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration

F. Marincola, L. Miller, E. Wang, 2002, Genome Biology.

Strengths and Limitations of Laboratory Procedures for MicroRNA Detection

F. Marincola, E. Wang, J. Koshiol, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Commentary Strengths and Limitations of Laboratory Procedures for MicroRNA Detection

F. Marincola, Yingdong Zhao, Jill Koshiol, 2010 .

A gene expression signature associated with survival in metastatic melanoma

F. Marincola, S. Bicciato, A. Callegaro, 2006, Journal of Translational Medicine.